Growth differentiation factor-15 and its role in diabetes and cardiovascular disease.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanisms and clinical biomarker potential without systematic review methodology
PubMed 33317942 · doi:10.1016/j.cytogfr.2020.11.002
What was done
This narrative review synthesized existing literature on growth differentiation factor-15 (GDF-15), focusing on its signaling pathways and physiological roles in regulating metabolism, insulin sensitivity, and the cardiovascular system.
What was found
The abstract reports no quantitative metrics or effect sizes. It notes that GDF-15 levels are consistently elevated in diabetes and cardiovascular disease, supporting its potential utility as a biomarker. Concurrently, cited literature indicates protective functions of GDF-15 in mitigating inflammation, improving endothelial cell function, enhancing insulin sensitivity, limiting weight gain, and conferring cardioprotection during myocardial infarction.
Why it matters
It highlights GDF-15 as both an indicator of cardiometabolic disease burden and an active cytokine with potential protective and therapeutic roles across metabolic and vascular pathways.
Limits
The abstract describes a non-systematic narrative review with no defined search protocol, study inclusion criteria, or risk-of-bias appraisal. No primary quantitative data, sample sizes, or patient cohort details are provided.
Cited by
- supports Circulating GDF15 levels are elevated in cancer, Alzheimer's disease, diabetes, hypertension, and heart disease.